BIOANALYTICAL METHOD FOR ESTIMATION OF TERIFLUNOMIDEIN HUMAN PLASMA
DOI:
https://doi.org/10.22159/ijpps.2022v14i9.45151Keywords:
Teriflunomide, HPTLC, Protein precipitation, Rilpivirine, BioanalyticalAbstract
Objective: Teriflunomide is used for the treatment of multiple sclerosis and is available in 7mg and 14mg tablets. This study aimed to develop and validatea simple and economical HPTLC method for the estimation of Teriflunomide in human plasma.
Methods: HPTLC method was developed using toluene: ethyl acetate: acetic acid as the mobile phase and the stationary phase was a TLC plate precoated with silica gel 60 F254. The detection wavelength set was 294nm. The sample preparation involved a simple protein precipitation technique with Acetonitrile as a protein precipitating agent, the internal standard selected was Rilpivirine.The validationwas carried out as per bio-analytical method guidelines.
Results: The Rf value for Teriflunomide was found to be 0.46±0.04. The linearity range was observed from 10-60 µg/ml with a regression coefficient value of 0.9819. The developed method was validated for various parameters like specificity, linearity, accuracy, precision, recovery, and stability.
Conclusion: The developed method is simple, specific, accurate, and economical for the estimation of Teriflunomide in human plasma.
Downloads
References
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 54684141, Teriflunomide; [cited 2022 Apr. 24]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Teriflunomide
Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. 2014 Apr; 74 (6): 659-74. Doi: 10.1007/s40265-014-0212-x.
Jiwon Oh, Paul W. O’Connor. Teriflunomide. Neurology: Clinical Practice. 2013 Aug; 3(4): 275. Doi: 10.1212/CPJ.0b013e318296f299.
Rakhila H, Rozek T, Hopkins A, Proudman S,Cleland L, James M, Wiese M. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis.2011 Jan 26;55: 325-331.
Parekh JM, Vaghela RN, Sutariya DK, Sanyal M, Yadav M, Shrivastav PS.Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 2010 Jun 25;878: 2217 – 2225.
Xueting Y, Yang L, Ling S, Ji J, Fei X, Dongyang L, Pei H.Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. Biomedical Chromatography. 2018.
Suneetha A and Raja RK. Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate, and fampridine in human plasma: application to rat pharmacokinetic study. Biomedical Chromatography. 2016 Feb 1.
Rule GS, Rockwood AL, and Johnson-Davis KL. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma. In: Langman LJ, Snozek CLH, editor. LC-MS in Drug Analysis – Part of Methods in Molecular Biology book series; Springer; 2018;75 – 83.
Filali AA, Lunven C, Turpault S, Beyer YJ, Amy O, Astrid D, Neli B, Ger-Jan S, Francesca B.Dried Blood Spot Methodology in Combination with Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide. Therapeutic Drug Monitoring (Lippincott Williams and Wilkins Open Access). 2016.
Suneetha A and Rajeshwari RK.Prescriptive Oriented Drug Analysis of Multiple Sclerosis Disease by LC-UV in Whole Human Blood. Journal of Chromatographic Science. 2015 July 15; 1 – 10.
Rule GS, Rockwood AL, and Johnson-Davis KL. Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma. In: Garg U, editor. Clinical application ofMass Spectrometry in Drug Analysis:Methods and Protocols, Methods in Molecular Biology. New York: Springer;2016. 195 - 203.
Raouf AA. Development & validation of analytical methods for the determination of some drugs used for musculoskeletal system disorders & osteoporosis therapy. Thesis Cairo University; Egypt; 2019.
Ramya SS, Subrahmanyam CVS, Shyam SR. Bioanalytical RP-HPLC method development and validation of Clopidogrel bisulfate in Wistar rat plasma and its application to pharmacokinetic study. International Journal of Applied Pharmaceuticals. 2021 Nov 17; 14 (1): 106-111.
Patil PK, Dr. Damle M. Stability indicating HPTLC method for analysis of Teriflunomide. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 May 31; 13 (6): 4926-4931.
Kadian N, Rama RKS, Rashid M, Malik MY, Taneja I,Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for the pharmaceutical industry. Journal of Pharmaceutical and Biomedical Analysis. 2016 Mar 25; 126: 97.
U.S Department of Health and Human services food and drug administration.Bioanalytical Method Validation Guidance for Industry [Internet]. USA: USFDA; 2018 Aug. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
Shah SK, Dey S, De S. Simultaneous determination of Atorvastatin and Atenolol in rabbit plasma by RP-HPLC method and its application in pharmacokinetic study. International Journal of Current Pharmaceutical Research; India; 2022 Jan 10; 14 (2): 72-78.
Tijare LK, Rangari NT, Mahajan UN.A Review onBioanalytical method development and validation. Asian Journal of Pharmaceutical and Clinical Research; India; 2016 Aug 24; 9 (suppl. 3); 6-10.
Pravallika KE, Prameela RA, Ratna KM.Bioanalytical method development and validation ofEntrectinib in rat plasma by Liquid Chromatography-Tandem Mass Spectrometry. Asian Journal of Pharmaceutical and Clinical Research; India; 2020 Sept 22; 13 (11); 155-163.
Published
How to Cite
Issue
Section
Copyright (c) 2022 MRINALINI C. DAMLE, POOJA GURAV
This work is licensed under a Creative Commons Attribution 4.0 International License.
